Microtubules Regulate Hypoxia-inducible Factor-1 alpha Protein Trafficking and Activity IMPLICATIONS FOR TAXANE THERAPY
Por:
Carbonaro, M, Escuin, D, O'Brate, A, Thadani-Mulero, M, Giannakakou, P
Publicada:
6 abr 2012
Resumen:
Disruption of the microtubule cytoskeleton impairs tumor angiogenesis by inhibiting the hypoxia-inducible factor (HIF1 alpha) pathway. However, the signaling cascade linking microtubule disruption to HIF-1 alpha inactivation has not been elucidated. Here, we show that microtubule-targeting drug (MTD) treatment impaired HIF-1 alpha protein nuclear translocation, which significantly down-regulated HIF transcriptional activity. We provide strong evidence that HIF-1 alpha protein associates with polymerized microtubules and traffics to the nucleus, with the aid of the dynein motor protein. Together, these data suggest that microtubules are critically involved in the nuclear trafficking and transcriptional activity of HIF-1 alpha. We also show that the connection between the microtubule cytoskeleton and HIF-1 alpha regulation is lost in renal cell carcinoma (RCC), where HIF-1 alpha is overexpressed because of mutations in the von Hippel Lindau (VHL) tumor suppressor protein. Specifically, we show that MTD treatment of RCC cells did not impair HIF-1 alpha nuclear accumulation or transcriptional activity, and had no effect on the polysome association profile of HIF-1 alpha. Interestingly, we found that HIF-1 alpha protein did not bind microtubules in RCC. Moreover, restoration of VHL function failed to restore the ability of MTDs to inhibit HIF-1 alpha, suggesting that VHL does not contribute to this phenotype. Together, these results suggest that HIF-1 alpha regulation is microtubule-independent, and likely contributes to the chemoresistant nature of RCCs. Further understanding of the microtubule-dependent HIF-1 alpha regulation, and lack thereof in RCC, is essential given the impor-tance of HIF-1 alpha in tumor biology, and the widespread use of MTDs in clinical oncology.
Filiaciones:
Carbonaro, M:
Cornell Univ, Weill Med Coll, Div Hematol & Med Oncol, Dept Med, New York, NY 10065 USA
Escuin, D:
Institut d’Investigació Biomèdica Sant Pau (IIB SANT PAU), Sant Quintí 77-79, 08041 Barcelona, Spain
O'Brate, A:
Cornell Univ, Weill Med Coll, Div Hematol & Med Oncol, Dept Med, New York, NY 10065 USA
Thadani-Mulero, M:
Cornell Univ, Weill Med Coll, Div Hematol & Med Oncol, Dept Med, New York, NY 10065 USA
Giannakakou, P:
Cornell Univ, Weill Med Coll, Div Hematol & Med Oncol, Dept Med, New York, NY 10065 USA
Hybrid Gold, Green Published
|